Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)

Active

Contract Opportunity

Amendment 5: PowerPoint presentation template

The purpose of this amendment is to provide the template for the PowerPoint presentation. Please see the Attachments section for the template.

Amendment 4: PowerPoint presentation

The purpose of this amendment is to add a virtual PowerPoint presentation to the evaluation process. This additional step requires submission of PowerPoint presentation slides, a Gantt chart, and an optional appendix in PDF format. For full details, please see the revised ISO, with changes identified in red font, attached to this amendment.

Please note, the deadline for the PowerPoint presentation submission is December 22, 2025 at 3:00PM E.T. The virtual PowerPoint presentations are expected to be held from January 5th to January 16th, 2026.

----------------------------------------------------------------------------------------------------------------

Amendment 3: Team Organization and Capabilities Section

The purpose of this amendment is to clarify that the following information, requested in the Teaming Organization and Capabilities section of the Solution Summary, may be included in the Table for Key Personnel:

Provide the name, position, and institution of each key team member and describe in 1-2 sentences the skills and experience they bring to the team.

If included in the Table for Key Personnel, this information will not count towards the (3) page Solution Summary page limit, however, the Table for Key Personnel must still not exceed (1) page in length.

In addition, the Q&A deadline is extended to October 30, 2025 at 11:59PM ET.

----------------------------------------------------------------------------------------------------------------

Amendment 2: Changes to the ISO

The purpose of this amendment is to amend the THRIVE ISO. An updated version of the ISO and an updated version of the ISO with tracked changes are included as attachments. Changes to the ISO include:

1. Cost share is now strongly encouraged instead of mandatory.


2. Multi-party teaming arrangements are no longer required.


3. ARPA-H's involvement with regulatory facilitation has been clarified.

Please review the amended ISO for all changes.

----------------------------------------------------------------------------------------------------------------

Amendment 1: Added the Frequently Asked Questions (FAQ) to the list of attachments.

----------------------------------------------------------------------------------------------------------------

The Advanced Research Projects Agency for Health (ARPA-H) Treating Hereditary Rare diseases with In Vivo precision genetic mEdicines (THRIVE) program envisions a future where patients can opt for one-time therapeutic interventions designed to slow, reverse, or cure disease, harnessing revolutionary technologies and a rapidly evolving understanding of the genetic underpinnings of the biological processes that lead to disease.

Interested parties are invited to review the attached THRIVE Innovative Solutions Opening (ISO) ARPA-H -SOL-25-122.

For detailed information regarding Proposers' Day review Special Notice (SN) ARPA-H-SN-25-131.

Solution summaries are due October 31, 2025, 11:59 PM ET.

For more information about THRIVE, please visit:https://arpa-h.gov/explore-funding/programs/thrive

Attachments/Links